Seelos Therapeutics (NASDAQ:SEEL) dosed the first patient in Part 2 of its registrational proof-of-concept study of SLS-002 (intranasal racemic ketamine) for acute suicidal ideation and behavior in patients with major...
UNITY Biotechnology (NASDAQ:UBX) announced positive data from its Phase 1 safety study of UBX1325 in patients with advanced disease from diabetic macular edema (DME) or wet age-related macular degeneration (AMD) for...
Titan Pharmaceuticals (NASDAQ:TTNP) reported that an in vivo study of its ProNeura-based human kappa-opioid receptor agonist, TP-2021, implant in an established itch-induced mouse model has demonstrated the...
CymaBay Therapeutics (NASDAQ:CBAY) announced positive data at The International Liver Congress from its previously completed Phase 2 study and the ENHANCE Phase 3 study of seladelpar in patients with primary biliary...
A peer-reviewed paper authored by clinicians and researchers from Germany’s ALTA Klinik and the University Hospital, LMU Munich, and published in Urologic Oncology illustrates that Profound Medical’s...
atai Life Sciences (NASDAQ:ATAI) priced an initial public offering of 15 million common shares at $15 each for gross proceeds of $225-million. In its first day of trading on June 18, the stock jumped $4.45, or 29%, to...
A $47-million series A financing from Versant Ventures and RA Capital Management launched LENZ Therapeutics, with a lead late-stage clinical program for presbyopia. Proceeds from the financing will be used to progress...
Clearside Biomedical (NASDAQ:CLSD) reported positive safety results from Cohort 1 of OASIS, its ongoing Phase 1/2a clinical trial of CLS-AX, an axitinib injectable suspension, which is administered by suprachoroidal...
Lucid Psycheceuticals inked a world-wide license agreement with Toronto’s University Health Network (UHN), Canada’s top research hospital, granting Lucid exclusive rights to novel compounds for therapeutic applications...
Hepion Pharmaceuticals (NASDAQ:HEPA) is set to join the Russell Microcap Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the U.S. market opens on June 28. Membership in the...
A systematic review and meta-analysis published in the April 30, 2021 issue of The Lancet strengthens evidence that fractional dose delivery is a viable alternative to full dose inactivated polio vaccine (IPV) and...
Lineage Cell Therapeutics (NASDAQ, TASE:LCTX) reported that restoration of retinal tissue was observed in two additional patients enrolled in the company’s Phase 1/2a study of its lead product candidate, OpRegen. ...
An article describing Ripple Therapeutics’ Epidel technology platform entitled, “Polymer-Free Corticosteroid Dimer Implants for Controlled and Sustained Drug Delivery,” was recently published in the peer-reviewed...
Seelos Therapeutics (NASDAQ:SEEL) received European orphan drug designation for SLS-005 in amyotrophic lateral sclerosis (ALS) from the European Medicines Agency Committee for Orphan Medicinal Products. Under orphan...
KA Imaging signed a U.S. distribution agreement with Ohio-based Alpha Imaging for its Reveal 35C portable dual-energy X-ray detector. Alpha Imaging is one of the largest distributors of medical imaging equipment in the...
111 Inc. (NASDAQ:YI), a leading digital healthcare platform in China, posted net revenue of RMB2.6 billion ($396-million U.S.) for the first quarter of 2021, an increase of 64.7%, compared with the same quarter in 2020...
Closely-held KA Imaging installed two new mobile X-ray units in the University Health Network of Toronto to enhance current clinical studies and support patient care, with one unit is being used at the Princess Margaret...
Seelos Therapeutics (NASDAQ:SEEL) reported positive data from Part 1, the open-label cohort, of its potentially registrational proof-of-concept study of SLS-002, demonstrating a significant treatment effect and a well...
Arctic Vision of Shanghai and Japanese-based ActualEyes announced an exclusive licensing agreement for Arctic Vision to develop and commercialize ActualEyes’ lead product candidate, AE-101, for the treatment of...
Sio Gene Therapies (NASDAQ:SIOX) is presenting new biomarker data from the company’s study of AXO-AAV-GM1, its adeno-associated viral vector (AAV)9-based gene therapy candidate for the treatment of GM1 gangliosidosis...
Clene (NASDAQ:CLNN) presented positive blinded interim efficacy data from its ongoing Phase 2 RESCUE-ALS clinical trial evaluating the efficacy, safety, pharmacokinetics and pharmacodynamics of CNM-Au8 in the treatment...
Profound Medical (NASDAQ:PROF; TSX:PRN) signed a multi-site imaging center agreement for its TULSA-PRO device with Akumin (NASDAQ, TSX:AKU), a leading provider of freestanding, fixed-site outpatient diagnostic imaging...